Clinical trials: H Pylori Eradication
Immune Thrombocytopenia
Effects of Helicobacter Pylori Eradication in Children With Chronic Immune Thrombocytopenic Purpura
Thrombocytopenia refers to a reduction in platelet count to (<150 × 109/L). Immune thrombocytopenic purpura is an acquired autoimmune disorder defined by isolated thrombocytopenia and the exclusion of other causes of…
- Trial name
- NCT03172676
- Testing
- Amoxicillin 50 mg/kg/day in 2 divided doses for 14 days., Clarithromycin 15 mg/kg/day in 2 divided doses for 14 days., Proton pump inhibitor 1 mg/kg/day in 2 divided doses 1 month
- Where
- Egypt
- Volunteers
- 75 people
- Sponsor
- Assiut University
Gram-Negative Bacterial Infections, Helicobacter Infections
Efficacy and Safety Study of Finafloxacin Used in Helicobacter Pylori Infected Patients
The primary objective of this study is to compare the H. pylori eradication rates with Finafloxacin in combination with Amoxicillin or Esomeprazole.
- Conditions
- Gram-Negative Bacterial Infections, Helicobacter Infections, Dyspepsia
- Trial name
- FLASH (NCT00723502)
- Testing
- Finafloxacin + Amoxicillin, Finafloxacin + Esomeprazole
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- MerLion Pharmaceuticals GmbH
Helicobacter Pylori Infection
Compare Sequential and Quadruple Therapy for the Eradication of Helicobacter Pylori in Korea
1. To compare 10-day sequential therapy and 14-day modified bismuth quadruple therapy and to establish more effective first-line regimen for the eradication of Helicobacter pylori in Korea. 2. To evaluate the effect of H.
- Trial name
- NCT02159976
- Testing
- Pantoprazole, Amoxicillin, Clarithromycin
- Where
- South Korea
- Volunteers
- 390 people
- Sponsor
- Seoul National University Bundang Hospital
Helicobacter Pylori Infection
Comparison of Two Novel First-line Anti-Helicobacter Pylori Therapy
The Asian-Pacific Consensus Report has recommended that proton pump inhibitor (PPI)-clarithromycin-amoxicillin or metronidazole treatment for 7 to14 days is the first choice treatment for H pylori infection.
- Trial name
- NCT03383003
- Testing
- Nexium, Amolin, Klaricid
- Where
- Taiwan
- Volunteers
- 240 people
- Sponsor
- Chang Gung Memorial Hospital
Healthy Volunteers, Patients
Drug Interaction Study on Linaprazan Glurate Capsules
This study is a drug-drug interaction (DDI) investigation involving Linaprazan Glurate capsules and a combination of clarithromycin tablets, amoxicillin capsules, and bismuth potassium citrate capsules.
- Trial name
- NCT07294846
- Testing
- Linaprazan Glurate Capsules, Bismuth Potassium Citrate Capsules, Amoxicillin Capsules
- Where
- China
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Jiangsu Sinorda Biomedicine Co., Ltd
Therapeutic Duration, Helicobacter Pylori
Optimal Duration of Antimicrobial Susceptibility Test (AST) Guided Rescue Therapy for Helicobacter Pylori Infection
Strongly evidence supports that H. pylori eradication is an effective approach to reduce the incidence of those pathologies. However, due to the increasing resistance rates to antibiotics, failures of H.
- Conditions
- Therapeutic Duration, Helicobacter Pylori, Antimicrobial Susceptibility Test, Eradication
- Trial name
- NCT02934048
- Testing
- 7-day triple regimen guided by AST, 10-day triple regimen guided by AST, 14-day triple regimen guided by AST
- Volunteers
- 700 people
- Sponsor
- Shandong University
Helicobacter Pylori Infection, Traditional Chinese Medicine
Eradication of Helicobacter Pylori With Bismuth Agent Quadruple and Traditional Chinese Medicine
This study is a prospective randomized case-control study. Six hundred patients who were firstly diagnosed as Helicobacter pylori infection will be selected, and then randomly assigned into case group and control group.
- Conditions
- Helicobacter Pylori Infection, Traditional Chinese Medicine, Eradication
- Trial name
- NCT05586464
- Testing
- Ban xia xie xin Decoction and bismuth quadruplicate group, Bismuth quadruplicate group
- Volunteers
- 600 people
- Sponsor
- Liaocheng People's Hospital
Helicobacter Infections, Gastritis
Tailored Treatment of H. Pylori Infection Based Polymorphisms of CYP2C19 and 23S rRNA of H. Pylori
The eradication rate of the standard H. pylori eradication therapy (such as the triple therapy with a proton pump inhibitor [PPI], amoxicillin and clarithromycin) depends on bacterial susceptibility to clarithromycin and…
- Conditions
- Helicobacter Infections, Gastritis, Gastric Ulcer, Duodenal Ulcer
- Trial name
- NCT00149084
- Testing
- Lansoprazole, clarithromycin, amoxicillin
- Where
- Japan
- Volunteers
- 296 people
- Sponsor
- Hamamatsu University
Helicobacter Pylori Infection
Efficacy of 7-day Versus 14-day Bismuth Quadruple Therapy for the Eradication of Helicobacter Pylori（SHARE2302)
Helicobacter pylori (H. pylori) infection is a common global infectious disease of the gastrointestinal tract. Helicobacter pylori eradication can effectively prevent the development of gastric cancer.The researchers collect…
- Trial name
- NCT05997433
- Testing
- 7days bismuth quadruple, 14 days bismuth quadruple
- Where
- China
- Volunteers
- 254 people
- Sponsor
- Shandong University
Gut Resistome
Effect of Probiotics on the Fecal Resistome During Helicobacter Pylori Eradication Therapy
Eradication therapy against Helicobacter pylori (Hp) carries adverse effects, such as altering the intestinal microbiota's structure and function and selecting commensals and pathogens resistant to antibiotics.
- Trial name
- NCT04786938
- Testing
- Saccharomyces Boulardii-Containing Product in Oral Dose Form
- Volunteers
- 72 people
- Sponsor
- Universidad San Francisco de Quito
Helicobacter Pylori Infection
Antibiotic Combination for H. Pylori Eradication in Penicillin-allergic Patients
This randomized controlled clinical trial will compare the eradication efficacy of bismuth quadruple therapy containing clarithromycin+metronidazole, clarithromycin+levofloxacin, or metronidazole+levofloxacin for Helicobacter…
- Trial name
- NCT05023577
- Testing
- Rabeprazole, Bismuth potassium citrate, Metronidazole
- Where
- China
- Volunteers
- 504 people
- Sponsor
- Shanghai Zhongshan Hospital
Helicobacter Pylori Infection
Tailored Juice-guided Eradication Therapy
In this study, the investigators aim to investigate the efficacy of tailored anti-microbial susceptibility guided-therapy via gastric juice PCR, compared with empirical standard triple therapy.
- Trial name
- HP (NCT04061447)
- Testing
- susceptibility-guided therapy, empirical clarithromycin-based triple therapy
- Where
- Taiwan
- Volunteers
- 182 people
- Sponsor
- Kaohsiung Medical University
Mucosa-Associated Lymphoid Tissue Lymphoma
Prospective Study of Frontline H Pylori Eradication in the Treatment of Early-stage Extragastric MALT Lymphoma
Gastric low-grade mucosa-associated lymphoid tissue lymphoma (MALToma) is associated with Helicobacter pylori (HP) infection, and around 70% of these tumors can be cured by HP eradication therapy (HPE).
- Trial name
- NCT02987127
- Where
- Taiwan
- Volunteers
- 21 people
- Sponsor
- National Taiwan University Hospital
Helicobacter Pylori
7-Day Vonoprazan, High-Dose Amoxicillin, and Bismuth Therapy
The 2024 American College of Gastroenterology (ACG) Clinical Guideline recommends a 14-day vonoprazan-amoxicillin (VA) regimen, consisting of vonoprazan 20 mg twice daily with amoxicillin 1000 mg three times daily, as a…
- Trial name
- JSHERO4 (NCT07232095)
- Testing
- VAB-7, VA-14
- Where
- China
- Volunteers
- 316 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Gastritis, H Pylori Infection
Helicobacter Pylori Eradication With Clostridum Butyricum Capsule and Bacillus Coagulans Tablets
This study aims at evaluating efficacy Clostridum Butyricum Capsule and Bacillus Coagulans Tablets in H. pylori eradication. It is hypothesized that Clostridum Butyricum Capsule , Bacillus Coagulans Tablets monotherapy or…
- Conditions
- Gastritis, H Pylori Infection, Dyspepsia
- Trial name
- NCT03857425
- Testing
- Clostridum Butyricum Capsule, Bacillus Coagulans Tablets, Clostridum Butyricum Capsule plus Bacillus Coagulans Tablets
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Xijing Hospital of Digestive Diseases
Helicobacter Pylori Infection
Sequential Therapy Versus Triple Therapy for Helicobacter Pylori Eradication: a Placebo-controlled Trial
To assess if a sequential treatment regimen better eradicates H. pylori than does a triple drug regimen in adults with dyspepsia or peptic ulcer disease.
- Trial name
- NCT00403364
- Where
- Italy
- Volunteers
- 300 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Helicobacter Pylori Infection, Tegoprazan
Efficacy and Safety of Tegoprazan Dual Therapy and Furazolidone-based Bismuth Quadruple Therapy for Helicobacter Pylori Eradication: A Prospective, Multicenter, Open-label, Randomized Controlled Clinical Study
To compare the efficacy and safety of Tegoprazan-amoxicillin dual therapy and bismuth quadruple therapy based on furazolidone in the treatment of Helicobacter pylori eradication, the eradication rate, patient compliance, and…
- Conditions
- Helicobacter Pylori Infection, Tegoprazan, Furazolidone
- Trial name
- NCT06340334
- Testing
- Tegoprazan-amoxicillin dual therapy
- Where
- China
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Nanjing First Hospital, Nanjing Medical University
Gastric Cancer Screening, Prevention and Control
Helicobacter Pylori Infection and Gastric Diseases in Lao PDR: First Community-Wide Population-Based Study
This study aims to determine the regional prevalence of Helicobacter pylori infection, bacterial strain differences, and the prevalence of gastric cancer in two provinces of Laos, a multi-ethnic country where these factors may…
- Conditions
- Gastric Cancer Screening, Prevention and Control, Helicobacter Eradication, Helicobacter Infections
- Trial name
- NCT07340593
- Where
- Laos
- Volunteers
- 1,251 people, healthy volunteers welcome
- Sponsor
- Zero Helicobacter IGAN Network
Helicobacter Pylori Infection, Dysbiosis
The Efficacy of 10-day and 14-day Bismuth-based Quadruple Therapy in First-line H. Pylori Eradication
Helicobacter pylori (H. pylori) infection is the major cause of gastritis, peptic ulcer disease, and gastric cancer in adults. Bismuth-based quadruple therapy is recommended by a recent review to be the first-line treatment for…
- Conditions
- Helicobacter Pylori Infection, Dysbiosis, Probiotics
- Trial name
- Bsm10 (NCT04527055)
- Testing
- Bismuth Subcitrate 120 MG Oral Tablet, Lactobacillus acidophilus and Bifidobacterium lactis Bb12, Esomeprazole 40mg
- Where
- Taiwan
- Volunteers
- 312 people
- Sponsor
- National Cheng-Kung University Hospital
Helicobacter Pylori Infection, Helicobacter Pylori Infected Patients
Study to Evaluate the Efficacy and Safety of DWP14012-based Triple Therapy in Eradication of Helicobacter Pylori
This study is designed to demonstrate the non-inferiority and verify the safety of DWP14012-based triple therapy compared to DWC202301-based triple therapy as the first-line eradication therapy in patients who are positive for…
- Conditions
- Helicobacter Pylori Infection, Helicobacter Pylori Infected Patients, Helicobacter Pylori Infected Subjects
- Trial name
- NCT06751121
- Testing
- DWP14012 40mg, DWC202301 30mg, Amoxicillin 1000mg
- Where
- South Korea
- Volunteers
- 461 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.